A new era in genomics

With a clearer understanding of each individual’s own genetic makeup, America’s Biopharmaceutical Companies are making groundbreaking innovations that deli

Portrait of Andrew Powaleny
Andrew PowalenyApril 26, 2017

A new era in genomics.

Personalized medicine has taken on a new meaning with the mapping of the human genome.

With a clearer understanding of each individual’s own genetic makeup, America’s Biopharmaceutical Companies are making groundbreaking innovations that deliver personalized medicines to patients. Personalized medicine is changing the course of treatment in a host of therapeutic areas – from oncology to cystic fibrosis; and holds incredible promise for diseases like Alzheimer’s. The completion of the Human Genome Project has catalyzed a new era of medicine, where scientific advances once unthinkable are today becoming a reality.

As part of the GOBOLDLY campaign, PhRMA is continuing our national dialogue series by discussing what genomics means in The New Era of Medicine with “Sequencing the Genome: Examining Modern Medicine” today, April 26th in partnership with The Atlantic. Over 40 percent of new medicines in development have the potential to be personalized medicines, and this event takes a deep dive into advances in genomic research and innovation, opportunities and challenges and what the future holds.

The program will be streamed live from 8:30 - 10:45 am ET, and those interested can join the conversation on Twitter with @PhRMA and #GoBoldy.

To learn more about the positive impact of the work being done by America’s biopharmaceutical companies, visit www.innovation.org.  

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.